Unreasonable Labs

Name: Unreasonable Labs
Brand: Unreasonable Labs

AI Native

Unreasonable Labs is an AI discovery engine (Unreasonable.DISCOVERY) that builds a unified world model to integrate literature, simulations, lab data, sensors, and enterprise datasets and supports multi-step reasoning workflows for hypothesis generation, decomposition, and iterative validation with human oversight.

Est 2025|Valuation $37M|Raised $13.5M

LinkedIn 1K|Website|FTEs 5|HQ Mountain View, CA

01Competitive Landscape

| Aspect | Unreasonable Labs | Schrödinger Platform | Insilico Medicine (Pharma.AI) | |---|---|---|---| | Starting Price | Not publicly listed | Not publicly listed (quote-driven licensing common) | Not publicly listed (deal-dependent) | | Best For | Cross-domain knowledge discovery workflows spanning physics/biology/materials/markets; teams seeking a collaborative AI discovery environment | Physics-based + ML computational workflows for molecular discovery/design (pharma/materials); teams needing an established simulation stack | Pharma/biotech teams seeking an integrated AI drug discovery suite across biology/chemistry/clinical forecasting | | Key Strength | Claims a unified representation across domains, emphasis on cross-domain analogies, and an integrated tool/simulation orchestration concept | Mature platform and established adoption; tight integration of physics-based methods and ML workflows | Drug discovery specialization; platform + services + pipeline/industry partnerships; focus on biological/chemical domains | | Key Weakness | Limited independent customer review footprint; unclear public security certifications; unclear pricing; claims about generating novel knowledge are hard to verify | Can be expensive and complex; some community discussions suggest selective case examples | Often enterprise-priced; platform economics vary by partnership/service model; may be less relevant outside biopharma | - Direct competitors and their key differentiators - Schrödinger differentiates with physics-based simulation credibility and an established product suite. - Insilico differentiates with a biopharma-oriented integrated suite (target ID, generative chemistry, clinical forecasting) and a business model that blends platform and services. - Owkin differentiates via biomedical focus and enterprise distribution (including third-party marketplace presence for some products). - Feature comparison: where Unreasonable may excel vs lag behind - Potential areas of strength (conditional on product delivery): - Cross-domain transfer and analogy workflows and a unified representation spanning multiple scientific domains plus market context. - Human-AI collaborative discovery workspaces with an emphasis on interpretability or traceability. - Likely gaps (based on maturity signals and lack of third-party validation): - Breadth of proven domain workflows and validated protocols compared with incumbents. - Enterprise compliance maturity and documented security posture. - Transparent external benchmarks tied to product performance. - Pricing comparison: value proposition vs alternatives - Insufficient public data for apples-to-apples pricing. - Buyers should expect: - Unreasonable Labs likely uses custom, quote-based pricing. - Schrödinger and enterprise biopharma platforms are also typically quote-based and may have higher total cost of ownership. - Market share and adoption trends - Not enough public evidence to estimate adoption for Unreasonable Labs. - Public profiles suggest a small, early-stage team consistent with pre-scale commercialization. - When customers choose competitors instead (and why) - When a buyer needs validated physics-based simulation pipelines today → Schrödinger often fits better. - When a buyer's objective is drug discovery pipeline acceleration with domain-specific modules → Insilico is more directly aligned. - When the buyer primarily needs governed enterprise data integration and lineage rather than an AI-based discovery layer → enterprise data platforms can be preferred.

01Competitive Landscape

Aspect	Unreasonable Labs	Schrödinger Platform	Insilico Medicine (Pharma.AI)
Starting Price	Not publicly listed	Not publicly listed (quote-driven licensing common)	Not publicly listed (deal-dependent)
Best For	Cross-domain knowledge discovery workflows spanning physics/biology/materials/markets; teams seeking a collaborative AI discovery environment	Physics-based + ML computational workflows for molecular discovery/design (pharma/materials); teams needing an established simulation stack	Pharma/biotech teams seeking an integrated AI drug discovery suite across biology/chemistry/clinical forecasting
Key Strength	Claims a unified representation across domains, emphasis on cross-domain analogies, and an integrated tool/simulation orchestration concept	Mature platform and established adoption; tight integration of physics-based methods and ML workflows	Drug discovery specialization; platform + services + pipeline/industry partnerships; focus on biological/chemical domains
Key Weakness	Limited independent customer review footprint; unclear public security certifications; unclear pricing; claims about generating novel knowledge are hard to verify	Can be expensive and complex; some community discussions suggest selective case examples	Often enterprise-priced; platform economics vary by partnership/service model; may be less relevant outside biopharma

Direct competitors and their key differentiators
- Schrödinger differentiates with physics-based simulation credibility and an established product suite.
- Insilico differentiates with a biopharma-oriented integrated suite (target ID, generative chemistry, clinical forecasting) and a business model that blends platform and services.
- Owkin differentiates via biomedical focus and enterprise distribution (including third-party marketplace presence for some products).
Feature comparison: where Unreasonable may excel vs lag behind
- Potential areas of strength (conditional on product delivery):
  - Cross-domain transfer and analogy workflows and a unified representation spanning multiple scientific domains plus market context.
  - Human-AI collaborative discovery workspaces with an emphasis on interpretability or traceability.
- Likely gaps (based on maturity signals and lack of third-party validation):
  - Breadth of proven domain workflows and validated protocols compared with incumbents.
  - Enterprise compliance maturity and documented security posture.
  - Transparent external benchmarks tied to product performance.
Pricing comparison: value proposition vs alternatives
- Insufficient public data for apples-to-apples pricing.
- Buyers should expect:
  - Unreasonable Labs likely uses custom, quote-based pricing.
  - Schrödinger and enterprise biopharma platforms are also typically quote-based and may have higher total cost of ownership.
Market share and adoption trends
- Not enough public evidence to estimate adoption for Unreasonable Labs.
- Public profiles suggest a small, early-stage team consistent with pre-scale commercialization.
When customers choose competitors instead (and why)
- When a buyer needs validated physics-based simulation pipelines today → Schrödinger often fits better.
- When a buyer's objective is drug discovery pipeline acceleration with domain-specific modules → Insilico is more directly aligned.
- When the buyer primarily needs governed enterprise data integration and lineage rather than an AI-based discovery layer → enterprise data platforms can be preferred.

Aspect

Unreasonable Labs

Schrödinger Platform

Insilico Medicine (Pharma.AI)

Starting Price

Not publicly listed

Not publicly listed (quote-driven licensing common)

Not publicly listed (deal-dependent)

Best For

Cross-domain knowledge discovery workflows spanning physics/biology/materials/markets; teams seeking a collaborative AI discovery environment

Physics-based + ML computational workflows for molecular discovery/design (pharma/materials); teams needing an established simulation stack

Pharma/biotech teams seeking an integrated AI drug discovery suite across biology/chemistry/clinical forecasting

Key Strength

Claims a unified representation across domains, emphasis on cross-domain analogies, and an integrated tool/simulation orchestration concept

Mature platform and established adoption; tight integration of physics-based methods and ML workflows

Drug discovery specialization; platform + services + pipeline/industry partnerships; focus on biological/chemical domains

Key Weakness

Limited independent customer review footprint; unclear public security certifications; unclear pricing; claims about generating novel knowledge are hard to verify

Can be expensive and complex; some community discussions suggest selective case examples

Often enterprise-priced; platform economics vary by partnership/service model; may be less relevant outside biopharma

Unreasonable Labs

01Competitive Landscape

02Market Map

01Competitive Landscape

02Market Map